Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced today, October 22, 2025, that data from its Phase 2 Explore‑CKD trial evaluating the safety and efficacy of 25 mg lorundrostat in patients with hypertension and comorbid chronic kidney disease will be presented in a late‑breaking clinical trials session at the American Society of Nephrology (ASN) Kidney Week 2025.
The presentation will take place during the ASN Kidney Week conference, scheduled for November 6‑9 in Houston, Texas, and will be part of a late‑breaking session that highlights emerging data from the company’s pivotal program. In addition, data from Mineralys’ Phase 3 Launch‑HTN pivotal trial will be featured in the ASN Kidney Week “Best of the Journal of the American Medical Association and the New England Journal of Medicine” program on November 7 from 2:00 PM to 4:00 PM CST in Grand Ballroom A of the George R. Brown Convention Center.
Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor designed to treat uncontrolled and resistant hypertension, chronic kidney disease, and obstructive sleep apnea. The announcement of the Explore‑CKD data presentation marks a significant milestone in the drug’s development, providing early visibility into its clinical performance and supporting the company’s strategy to advance toward regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.